Review of psychopharmacology
1 Department of pharmacy Kondala Zamre, Washim-444505, India.
2 Department of pharmacology, Shraddha institute of pharmacy, Washim, (MS) India 444505.
Review Article
GSC Biological and Pharmaceutical Sciences, 2023, 25(02), 365–371
Article DOI: 10.30574/gscbps.2023.25.2.0456
Publication history:
Received on 21 September 2023; revised on 19 November 2023; accepted on 21 November 2023
Abstract:
In India, one of the primary causes of non-fatal disease burden is psychopharmacological diseases. The prevalence of psychopharmacological disorders in India was one in seven. Despite being used to treat psychological disorders like anxiety, psychosis, depression, and mania, psychopharmacological medications can have unwanted side effects, including tardive dyskinesia, weight gain, weight loss, muscle cramps, dysphoria, gastrointestinal upset, eye problems, and issues with blood tests. We exposed numerous screening techniques for assessing psychopharmacological diseases such anxiety, depression, psychosis, and mania in the context of preclinical investigations in this study. These techniques are highly helpful for assessing psychopharmacological medications such as anti-anxiety, anti-psychotic, anti-depressant, and anti-manic medications.
Keywords:
Preclinical research; Anti-psychotics; Antidepressants; Anti-manic medications; Psychopharmacological diseases
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
